Welcome to Cellzome
Cellzome is a privately-owned drug discovery and development company and a leader in the use of chemical proteomics technology. We are using our technology to identify a new generation of drug candidates for the treatment of inflammatory diseases.
Collaboration exploits Cellzome's world-leading proteomics technology in epigenetics
Cambridge, United Kingdom and Heidelberg, Germany, 10th March 2010 - Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere™ technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response. ... more
Cambridge, United Kingdom and Heidelberg, Germany, 10th March 2010 - Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere™ technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response. ... more
Heidelberg, Germany, 23rd November 2009 - Cellzome announces that an article published today in Virology has shown that multiple cyclophilins - enzymes that facilitate protein folding - are involved in hepatitis C virus replication. The paper was published by scientists from Cellzome and Novartis Institutes of Biomedical Research (NIBR). In the study, two hepatitis C virus (HCV) drug candidates have been shown to interact with different cyclophilins and thus can attenuate viral replication. Interestingly, the different enzymes are found to participate in different cellular processes, the most prominent one being protein trafficking.
... more
Cambridge, UK and Heidelberg, Germany, 30th September 2009 - Cellzome Inc. announced today that it has successfully achieved the fourth milestone in its strategic alliance with GlaxoSmithKline. The achievement of this milestone triggers a further payment from GlaxoSmithKline. The amounts of these payments are undisclosed.
... more
Integrated chemical genetics and proteomics approach identifies new potential drug targets in Wnt pathway
Heidelberg, Germany, 16th September 2009 - Cellzome announces today, the publication entitled 'Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling' is now available online in Nature. The paper describes how Cellzome's quantitative chemical proteomics platform was used to identify a small molecule which plays a critical role in the regulation of the Wnt pathway. ... more
Heidelberg, Germany, 16th September 2009 - Cellzome announces today, the publication entitled 'Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling' is now available online in Nature. The paper describes how Cellzome's quantitative chemical proteomics platform was used to identify a small molecule which plays a critical role in the regulation of the Wnt pathway. ... more
| Date | Conference | Location |
|---|---|---|
| 04 Mar 2010 | Liquid Handling and Label Free Technologies | London |
| 08-10 Mar 2010 | BIOEurope | Barcelona |
| 03-06 May 2010 | BIO | Chicago |
| 06-07 May 2010 | Epigenetic World Congress | Boston |
| 23-27 May 2010 | ASMS | Salt Lake City |
| 27-28 May 2010 | 5th Annual Protein Kinases in Drug Discovery Conference | Boston |
| 02-04 Jun 2010 | ERBI Annual Conference | Cambridge, UK |
| 07-12 Jun 2010 | Keystone Conference: Innate Immunity - Mechanisms Linking with Adaptive Immunity |
Dublin |
| 14-15 Jun 2010 | 4th European Business Development Conference | Munich |
| 16-19 Jun 2010 | EULAR 2010 | Rome |